Seeking Alpha

Salix (SLXP -9.5%) shares slump on heavy trading after the FDA raises questions about the...

Salix (SLXP -9.5%) shares slump on heavy trading after the FDA raises questions about the drugmaker's non-constipation irritable bowel syndrome treatment Xifaxan ahead of a Nov. 16 committee meeting. Some experts believe the unexpected questions could complicate approval, although others expect the drug ultimately will be approved.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs